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Abstract
Variants at the interleukin 6 receptor (IL6R) gene regulate inflammation and are associated
with risk of coronary heart disease (CHD). The aim of the present study was to investigate
the effects of IL6R haplotypes on circulating levels of inflammatory biomarkers and risk of
CHD. We performed a discovery analysis in SHEEP, a myocardial infarction (MI) case con-
trol study (n = 2,774) and replicated our results in two large, independent European popula-
tions, PROCARDIS, a CHD case control study (n = 7,998), and IMPROVE (n = 3,711) a
prospective cardiovascular cohort study. Two major haplotype blocks (rs12083537A/G and
rs4075015A/T—block 1; and rs8192282G/A, rs4553185T/C, rs8192284A/C, rs4240872T/C
and rs7514452T/C—block 2) were identified in the IL6R gene. IL6R haplotype associations
with C-reactive protein (CRP), fibrinogen, IL6, soluble IL6R (sIL6R), IL6, IL8 and TNF-α in
SHEEP, CRP and fibrinogen in PROCARDIS and CRP in IMPROVE as well as association
with risk of MI and CHD, were analyzed by THESIAS. Haplotypes in block 1 were associat-
ed neither with circulating inflammatory biomarkers nor with the MI/CHD risk. Haplotypes in
block 2 were associated with circulating levels of CRP, in all three study populations, with fi-
brinogen in SHEEP and PROCARDIS, with IL8 and sIL6Rin SHEEP and with a modest,
non significant, increase (7%) in MI/CHD risk in the three populations studied. Our results
indicate that IL6R haplotypes regulate the circulating levels of inflammatory biomarkers.
Lack of association with the risk of CHD may be explained by the combined effect of SNPs
with opposite effect on the CHD risk, the sample size as well as by structural changes affect-
ing sIL6R stability in the circulation.
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Introduction
The interleukin 6 receptor gene (IL6R) region centered at rs8192284A/C, a functional SNP
causing a Asp358Ala aminoacid change in the membrane bound IL6R, has been associated
with the risk of coronary heart disease (CHD) [1–4], as well as with serum levels of inflamma-
tory biomarkers. In particular, the C allele is associated with lower levels of C-reactive protein
(CRP), fibrinogen [5] and with higher levels of interleukin 6 (IL6) [6] and soluble interleukin 6
receptor (sIL6R) [3,4]. These data indicate that IL6Rmay regulate inflammation and athero-
sclerosis. However the underlying mechanisms are still largely unknown.
Association of single SNPs with complex diseases leaves unexplored the effect exerted by
other genetic variants mapping on the same gene. In this respect haplotypes may be considered
as “super-alleles”, where the different genetic variants act in synergy [7,8]. Since the effect size
of each genetic variant on complex phenotypes is rather small, haplotypes may provide further
insights into mechanisms underlying the association of candidate genes with complex and in-
termediate phenotypes [9].
To disentangle the association of IL6R with inflammation and risk of CHD, we analyzed the
association of IL6R haplotypes with circulating levels of inflammatory biomarkers [CRP, fi-
brinogen, sIL6R, IL6, interleukin 8 (IL8) and TNF-α] and with the risk of myocardial infarction
(MI) and CHD. We performed our discovery study in the Stockholm Heart Epidemiology
study (SHEEP), a large case control study conducted in the greater Stockholm area, and repli-
cated the main findings in two independent, multicenter European studies: the Precocious
Coronary Artery Disease (PROCARDIS) study [10] and the carotid Intima-Media thickness
(c-IMT) and c-IMT Progression as Predictors of Vascular Events in a high risk European pop-
ulation (IMPROVE) study [11].
Materials and Methods
Study Populations
The SHEEP study is a population based case-control study designed to dissect both genetic and
environmental factors associated with the risk of MI [12]. Study design and population charac-
teristics have been fully reported elsewhere [13]. In the present investigation, only cases diag-
nosed with a MI, who survived at least 28 days (n = 1213) and age- and sex-matched controls
(n = 1561) were included. Measurements of hs-CRP, and TNF-α in serum and fibrinogen in
plasma were performed as described [14]. IL6, sIL6R and IL8 levels were measured in serum
using assays provided by MesoScale Diagnostic (Human Cytokine Assay, Ultra-Sensitive Kit,
MSD, Bethesda, USA), following the manufacturer´s protocol.
The PROCARDIS study recruited CHD cases and controls from Sweden, Germany, the
United Kingdom and Italy [10]. Briefly, cases (n = 5689) were defined as having had a diagno-
sis of MI or acute coronary syndrome before the age of 66 years. Control subjects (n = 2308)
were unrelated individuals, free from symptoms of CHD up to the age of 66 years and without
siblings diagnosed with CHD before 66 years. CRP and fibrinogen were measured as described
[10].
IMPROVE is a multicenter longitudinal European study, designed to investigate whether
progression of carotid IMT is an independent predictor of cardiovascular events. A detailed de-
scription of the study has been reported elsewhere [11]. Briefly, 3711 subjects, who were
asymptomatic for cardiovascular disease but had at least three established cardiovascular risk
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factors (dyslipidemia, hypertension, diabetes, smoking and family history of cardiovascular dis-
ease), were recruited in five European countries (Finland, Sweden, the Netherlands, France,
Italy). Incident cardiovascular events (n = 213) were recorded during a 3-year follow-up peri-
od. Genotype data were available for 3516 individuals (cases: 198 referent group: 3318). Hs-
CRP was measured as described [11].
Ethics
The SHEEP study was carried out in accordance with the Helsinki Declaration and approved
in 1991 by the Regional Ethics Review Board at Karolinska Institutet, Stockholm, Sweden. All
the study participants in the SHEEP gave their informed oral consent to be enrolled in the
study, since at the time the study was initiated (1992) no forms for the written consent were
available or in current use. Cases were informed about the study at the time they were dis-
charged from the hospital and controls were informed via mail. Participation was voluntary
and involved no evident risks and only study participants who agreed to participate in the
study received the questionnaire and were invited for the medical examination. This consent
procedure was approved by the Regional Ethics Review Board at Karolinska Institutet.
The PROCARDIS study was funded by the European Commission Framework 6 (FP6) pro-
gram. The study was carried out in accordance with the Helsinki Declaration and approved by
the Institutional Review Board (IRB) at each one of the 4 recruiting centers: (1) the Regional
Ethics Review Board at Karolinska Institutet, Stockholm in Sweden, (2) the IRB at the Universi-
ty of Munster, Munster, in Germany, (3) the IRB at the Mario Negri Institute, Milano in Italy
and (4) the IRB at the University of Oxford, Oxford, United Kingdom. All study participants
provided their written informed consent to participate in the study, a procedure approved by
each one of the local ethical committee. A complete list of the participating and contributing
centers is available at http://www.procardis.org.
The IMPROVE study was funded by the Vth European Union (EU) program. The study was
carried out in accordance with the Helsinki Declaration and approved by the IRB at each one
of the seven recruiting centers: (1) the Regional Ethics Review Board at Karolinska Institutet,
Stockholm Sweden, (2) IRB at the Groupe Hôpitalier Pitie-Salpetriere, Paris, France, (3) the
IRB Comitato Etico delle Aziende Sanitarie della regione Umbria, Perugia and (4) the IRB at
the Ospedale Niguarda Ca´Granda, Milano, both in Italy, (5) the IRB at the University Hospital
Groningen, Groningen, the Netherlands, (6) the IRB Hospital District of Northern Savo and
(7) and the IRB at University of Eastern Finland, both in Kuopio, Finland. Each participant
provided two different written consents one for general participation in the study and one
for genotyping.
Single Nucleotide Polymorphism (SNP) genotyping and haplotype
generation
SNP selection, genotyping and definition of haplotype blocks in the discovery cohort,
the SHEEP study. Ten SNPs were originally genotyped by MALDI-TOF (Matrix Adsorbed
Laser Desorption-Ionisation-Time Of Flight) [15], on the Massarray Analyzer platform
(Sequenom, Mutation Analysis Facility at Karolinska Institutet) based upon HapMap data re-
lease 24 Nov08 (rs4845617A/G at the 5´UTR, rs12083537A/G, rs12090237G/A, rs4075015A/
T, rs4601580A/T, rs8192282G/A, rs4553185T/C, rs4537545C/T, rs4240872T/C and
rs7514452T/C at the 3´UTR). Genotype data were integrated with eight additional SNPs geno-
typed in the SHEEP included in the Illumina 200K CardioMetabochip [16] and mapping at
IL6R (rs7553796C/A, rs7518199C/A, rs4453032A/G, rs4845625C/T, rs6689393G/A,
rs4129267C/T, rs8192284A/C and rs4072391C/T).
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IL6R haplotype blocks were generated by Haploview [17], using the algorithm proposed by
Gabriel [18]. Two haplotype blocks were identified in the SHEEP study (Fig. 1). The Haploview
tagger function was the used to identify redundant SNPs. SNPs were considered redundant if
the pairwise LD (r2) was0.8.
Rs12083537A/G and rs4075015A/T were retained in the first haplotype block (block 1) and
rs8192282G/A, rs4553185T/C, rs8192284A/C, rs4240872T/C and rs7514452T/C in the second
haplotype block (block 2). Three SNPs (rs4845617A/G, rs12090237G/A and rs4601580A/T)
did not belong to any of the two blocks.
Replication in the PROCARDIS and IMPROVE study. To replicate this analysis, four-
teen IL6R SNPs genotyped with the Illumina 1M and 610K chips and available in the PRO-
CARDIS study (rs12083537A/G, rs4075015A/T, rs12090237G/A, rs4601580A/T, rs8192282G/
A, rs7553796C/A, rs7518199C/A, rs4553185T/C, rs4537545C/T, rs4129267C/T, rs8192284A/
C, rs4240872T/C, rs7514452T/C and rs4072391C/T) were also run in Haploview. The two hap-
lotype blocks were confirmed in the PROCARDIS study. The tagger function retained
rs12083537A/G and rs4075015A/T in the haplotype block 1 and rs8192282G/A, rs4553185T/
C, rs8192284A/C, rs4240872T/C in haplotype block2. To be consistent with the analysis per-
formed in the SHEEP, the SNP rs7514452T/C was also retained even if redundant.
Finally, eight IL6R SNPs genotyped with the Illumina 200K CardioMetabochip
(rs7553796C/A, rs7518199C/A, rs4453032A/G, rs4845625C/T, rs6689393G/A, rs4129267A/C,
rs8192284A/C and rs4072391C/T) mapping in the haplotype block 2 generated in the SHEEP
and PROCARDIS were available for the IMPROVE. The Haploview tagger function identified
Fig 1. Representative LD plot of the two haplotype blocks at IL6R in SHEEP. Two of the 18 SNPs are not shown: rs4537545 in full LD with rs8192284
and rs4845625 in full LD with rs6689393 (both r2>0.95).
doi:10.1371/journal.pone.0119980.g001
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rs7553796 C/A (pairwise LD with rs4553185T/C, r2 = 0.96), rs8192284A/C and rs4072391T/C
(pairwise LD with rs7514452T/C r2 = 0.98) as tagSNPs in the IMPROVE.
Haplotype generation in the SHEEP and in the replication cohorts. Haplotypes in block
1 and block 2 were inferred from the original genotype data using THESIAS v 3.1 [19] in the
SHEEP and in the two replication cohorts. To control the correct inference of the haplotype
from the genotype data, the haplotypic r2 value command in THESIAS was used and a r2 = 0.7
was set as cut off value, according to the program instructions. Haplotypes with a frequency
1% were excluded from the analysis. The haplotypic r2 value and the haplotype frequencies
in the three study populations are reported in S1 Table.
Statistical Analysis
Continuous variable are reported as mean and 95% confidence interval (CI), binary variables
are reported as percentages.
Haplotypes were inferred from the original genotype data and analyzed for association with
the circulating levels of inflammatory biomarkers and for association with the MI/CHD risk
using THESIAS v 3.1 [19].
Haplotypes were tested for association with serum/plasma levels of inflammatory biomark-
ers [CRP (mg/L), fibrinogen (g/L), IL6 (ng/ml), sIL6R (ng/ml), IL8 (pg/ml), and TNF-α (ng/L)
in SHEEP; CRP (mg/L) and fibrinogen (g/L) in PROCARDIS and CRP (mg/L) in IMPROVE]
in the healthy participants of the SHEEP, PROCARDIS and IMPROVE studies. Original data
were transformed on a natural log (CRP, fibrinogen, IL6, IL8, TNF-α) or square root scale
(sIL6R) to achieve and/or improve the normality of the distribution. Individuals with missing
data (genotype, biomarker measurement and covariates) were excluded from the analysis.
The final number of individuals included in the analysis for each biomarker is reported in the
S2 Table. The association of each haplotype with serum/plasma levels of the biomarkers is esti-
mated by a regression parameter and 95%CI where the effect of each haplotype is compared to
the most frequent haplotype that THESIAS sets as the intercept in the regression model. The
estimated regression parameters were adjusted by age and sex in SHEEP and by age, sex and
participating center in the PROCARDIS and IMPROVE studies. Data are reported as estimated
change in the circulating levels of the biomarker as compared to the reference haplotype. They
represent the antilog/power of the regression parameter and 95%CI and are expressed in the
original unit of measurement for each biomarker [20]. The variance in serum/plasma levels of
different inflammatory biomarkers explained by IL6R haplotypes was estimated from the
square of the ratio between the global and the residual standard error, derived from THESIAS´
analysis algorithm.
Risk estimates of MI/CHD associated with IL6R haplotypes were expressed as odds ratio
(OR) and 95% CI in the SHEEP and PROCARDIS studies and as hazard ratios (HR) and 95%
CI in the IMPROVE study. Risk estimates for MI were adjusted for age, sex and residential area
in the SHEEP study, and for age sex and participating centers in the PROCARDIS and
IMPROVE studies.
Significance threshold was set at p< 0.05 in the SHEEP study and association analyses were
replicated in the PROCARDIS and IMPROVE studies. No adjustments for multiple compari-
sons were made since haplotypes are highly interrelated.
Results
The demographic characteristics of the three study populations are summarized in Table 1.
Overall, prevalence of the cardiovascular risk factors was different among the three
IL6R Haplotypes, Inflammation and Risk of CHD
PLOSONE | DOI:10.1371/journal.pone.0119980 March 17, 2015 5 / 14
populations. Cardiovascular risk factors occurred more frequently among the cases than the
controls with the exception of hypertension in the SHEEP study.
IL6R haplotypes and serum CRP levels. Association of IL6R haplotypes with serum CRP
levels was tested in the control group of SHEEP and replicated in the controls of the PROCAR-
DIS and IMPROVE studies. The relative change in serum CRP levels (mg/L) associated with
one copy of each haplotype as compared to the reference haplotype is reported in Table 2.
Table 1. Demographic characteristics of the study participants in the three study populations.
SHEEP (N = 2774) PROCARDIS (N = 7997) IMPROVE (N = 3711)
Cases Controls Cases Controls Cases Referents
(N = 1231) (n = 1561) (N = 5689) (N = 2308) (N = 198) (N = 3318)
Man/Women 852/361 1054/507 4262/1425 1746/562 121/77 1571/1747
Age (mean (95%CI) 59.2 (58.8–59.6) 59.8 (59.4–60.1) 61.9 (61.7–62.1) 55.1 (54.6–55.4) 65.5 (64.7–66.3) 65.5 (64.7–66.3)
Hypertension (%) 46 52 88 43 75 68
Diabetes (%) 19 8 19 4 33 26
Smoking (%) 49 30 51 21 21 14
Hyperchol (%) 43 30 74 18 71 62
Obesity (%) 18 12 32 14 25 21
Hyperchol: hypercholesterolemia.
SHEEP: hypertension deﬁned as blood pressure >140/90 mmHg and/or self-reported and/or antihypertensive drug treatment; diabetes deﬁned as glucose
levels>6.7mmol/L and/or insulin or hypoglycemic drugs; smoking deﬁned as current smoking in the past two years; hypercholestesterolemia deﬁned as
serum level of total cholesterol 6.46 mmol/L and/or treatment with lipid lowering drugs; obesity deﬁned as body mass index>30kg/m2.
PROCARDIS: hypertension deﬁned as blood pressure >140/90 mmHg and/or self-reported and/or antihypertensive drug treatment; diabetes deﬁned as
self-reported. glucose levels>7.0mmol/L and/or insulin or hypoglycemic drugs; hypercholestesterolemia deﬁned as serum level of total cholesterol 6.46
mmol/L and/or treatment with lipid lowering drugs; obesity deﬁned as body mass index>30kg/m2.
IMPROVE: hypertension and hypercholesterolemia were self-reported at the time of enrollment; diabetes deﬁned as self reported and/or glucose
levels>7.0mmol/L and/or insulin or hypoglycemic drugs; smoking deﬁned as current smokers; obesity deﬁned as body mass index>30kg/m2
doi:10.1371/journal.pone.0119980.t001
Table 2. Association of IL6R haplotypes in block 1 and block 2 with differences in serum CRP levels (compared to the reference haplotype
where mean CRP (95%CI) are shown) in controls from the SHEEP and PROCARDIS and in block 2 from the IMPROVE study.
Block 1 SHEEP P PROCARDIS P
(n = 1088) (n = 2231)
12 1.15 (1.04–1.25) reference 1.05 (0.98–1.12) reference
11 +1.02 (0.96–1.10) 0.46 +1.03 (1.01–1.16) 0.21
21 +1.01 (0.92–1.10) 0.83 +0.98 (0.99–1.11) 0.46
Block 2 SHEEP PROCARDIS IMPROVE(95%CI) P Haplotype in IMPROVE
(n = 1052) (n = 2231) (n = 3316)
11211 1.11 (1.02–1.22) reference 1.05 (0.99–1.13) reference 0.98 (0.80–1.20) reference −12–1
12122 +1.08 (0.99–1.20) 0.07 +1.03 (0.97–1.09) 0.22 +1.08 (1.02–1.15) 0.004 −21–2
12111 +1.12 (1.01–1.23) 0.02 +1.06 (1.0–1.12) 0.03 +1.12 (1.05–1.22) 0.0001 −21–1
21111 +1.07 (0.97–1.16) 0.16 +1.06 (1.04–1.13) 0.03 +1.14 (1.06–1.22) 0.0003 −11–1
12121 +1.06 (0.89–1.27) 0.46 +1.09 (0.96–1.23) 0.14
Data represent the mean and relative 95%CI of the difference in serum CRP levels (mg/L) observed in the presence of one copy of each haplotype
conﬁgurations as compared to the reference haplotype. Genotype data from only three SNPs in block 2 were available in the IMPROVE study (rs7553796
C/A (pairwise LD with rs4553185T/C. r2 = 0.96) rs8192284A/C and rs4072391T/C (pairwise LD with rs7514452T/C r2 = 0.98).
doi:10.1371/journal.pone.0119980.t002
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Diplotypes in block 1 were neither associated with serum CRP levels in SHEEP controls, nor in
the PROCARDIS study (Table 2).
Allele 1 (A) at rs8192284, in haplotype block 2, has been previously associated with higher
serum CRP levels as compared to the 2 (C) allele [2–4,6]. As shown in Table 2, in SHEEP, (n =
1052), all haplotypes in block 2 carrying the A allele at rs8192284 were associated with a rela-
tive increase of about 1mg/L in CRP serum levels as compared to the reference haplotype
11211(GTCTT), carrying the alternate C allele.
Haplotype 12111 (GCATT) was associated with the largest increase in CRP serum levels
[+1.12mg/L (1.01–1.23) p = 0.02] as compared to the reference haplotype, 11211(GTCTT).
In PROCARDIS (n = 2231), haplotype 12111 (GCATT) and haplotype 21111 (ATATT)
were associated with an increase in CRP levels, of +1.06 mg/L (1.0–1.12), and +1.06 mg/L
(1.0–1.13), respectively, both p = 0.03, as compared to the most common haplotype 11211
(GTCTT).
In IMPROVE (n = 3316), the following three SNPs were used to generate the haplotype in
block 2 [rs7553796 C/A (pairwise LD with rs4553185T/C, r2 = 0.96), rs8192284A/C and
rs4072391T/C (pairwise LD with rs7514452T/C r2 = 0.98)]. All haplotypes were associated
with an average increase of 1 mg/L in CRP levels as compared to reference haplotype, as shown
in Table 2.
Overall, IL6R haplotypes explained 3% of the variance in serum CRP levels in SHEEP, 4% in
PROCARDIS and 3.4% in IMPROVE.
IL6R haplotypes and plasma fibrinogen levels
IL6R haplotypes were tested for association with plasma fibrinogen levels in SHEEP (n = 1319)
and PROCARDIS (n = 2230). Haplotypes in block 1 were not associated with fibrinogen levels
(S3 Table).
In SHEEP, haplotypes 12122 (GCACC) and 12111 (GCATT) in haplotype block 2 were as-
sociated with the largest difference in plasma fibrinogen levels (g/L) as compared to 1.46 (1.41–
1.52) at the reference haplotype (GTCTT, 11211) [with an increase (g/L) of 1.06 (+1.02–1.10),
p = 0.001 and +1.04 (1.0–1.08), p = 0.02, respectively]. Consistent with this, in PROCARDIS,
haplotypes 12122 (GCACC) and 12111(GCATT) were also associated with a relative increase
in plasma fibrinogen levels (+1.02 (0.98–1.04) and +1.02 (0.99–1.05) g/L, respectively), as com-
pared to the reference haplotype 11211 (GTCTT) [1.50 (1.43–1.58)], although the difference
did not attain statistical significance (p = 0.05).
IL6R haplotypes explained 3.5% and 4.4% of the variation in plasma fibrinogen in SHEEP
and PROCARDIS, respectively.
IL6R haplotypes and serum sIL6R, IL6, IL8 and TNF-α levels in SHEEP
No association was found between IL6R haplotypes in block 1 and sIL6R (Table 3).
IL6R haplotypes in block 2 were associated with differences in serum concentrations of
sIL6R (Table 3) in SHEEP (n = 1004). As shown in Table 3, all haplotypes carrying the 1 (A) al-
lele at rs8192284 were associated with reduced serum levels of sIL6R, and IL6R haplotypes ac-
counted for 9.2% of the variance of circulating sIL6R levels in SHEEP.
Haplotype 12111 (GCATT) in block 2 was associated with an increase in serum IL8 levels
[+1.11 (1–1.2), p = 0.03], as compared to the reference haplotype (S4 Table). No association
was observed between haplotypes in block 1 and serum IL8 levels.
Haplotypes in block 1 and in block 2 were not associated with differences in serum levels of
IL6 and TNF-α (S4 Table).
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IL6R haplotypes and risk of cardiovascular events. Table 4 shows the haplotype frequen-
cies in cases and controls and the risk of MI/CHD associated with the IL6R haplotypes in the
three studies. Haplotype 12111(GCATT) in block 2 was associated with a 7% increase in the
MI/CHD risk in the three study populations, although the result did not attain statistical signif-
icance. All the other haplotypes in block 1 and block 2 did not show a consistent association
with risk cardiovascular events in the three studies.
All the other haplotypes in block 1 and block 2 did not show a consistent association with
with risk cardiovascular events in the three studies.
Discussion
The data presented here represent the most comprehensive analysis of the role of IL6R haplo-
types in the regulation of circulating levels of inflammatory biomarkers and as a risk factor for
CHD. They indicate that IL6R haplotypes regulate serum levels of CRP, IL8 and sIL6R and
plasma levels of fibrinogen in healthy individuals and are associated with a modest, and in this
sample size, non-significant association with the risk of CHD in three, large independent
European populations.
IL6R encodes both the membrane bound receptor and the sIL6R. The membrane bound
IL6R regulates the synthesis and release of CRP and fibrinogen from hepatocytes in response
to IL6. We observed that haplotypes containing the A allele of rs8192284, which has formerly
been associated with higher circulating levels of CRP and fibrinogen as compared to the alter-
nate C allele [2–6,21], are consistently associated with an increase in the circulating levels of
CRP and fibrinogen as compared to the reference haplotype.
In the SHEEP study, we were also able to analyze the association of IL6R haplotypes with a
panel of inflammatory biomarkers. Even if our data are limited to a relatively small number of
individuals, they indicate that sIL6R haplotypes are not involved in the regulation of TNF-α
and IL6, two upstream regulators of IL6R [22,23]. This is consistent with the hypothesis of a se-
quential regulation of gene expression in the inflammatory cascade, where upstream genes reg-
ulate downstream mediators [13]. We did observe a modest effect of one IL6R haplotype on
IL8 serum levels. IL8 participates in the shedding of the sIL6R from the membrane bound re-
ceptor and is also a mediator of IL6 release in the early stage of the inflammatory process [22].
Table 3. Association of IL6R haplotypes in blocks 1 and 2 with difference in serum sIL6R levels in
controls from the SHEEP compared to the reference haplotype where mean sIL6R (95%CI) are
shown.
Block 1 (n = 1037) sIL6R (ng/ml) P
12 10.4 (9.4–12.7) reference
11 +0.01 (0.006–0.008) 0.26
21 −0.002 (0.008–0.03) 0.68
Block 2 (n = 1004)
11211 14.7 (12.6–16.8) reference
12122 −1.08 (-0.5–1.7) <1*10−6
12111 −0.68 (-0.31–1.18) <1*10−6
21111 −0.55 (-0.23–1.0) <1*10−6
12121 −0.68 (-0.16–1.55) 0.0001
Data represent the mean and relative 95%CI of the difference in serum sIL6R levels (ng/ml) observed in
the presence of one copy of each haplotype conﬁgurations as compared to the reference haplotype.
doi:10.1371/journal.pone.0119980.t003
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Replication of this association as well as functional studies are warranted to correctly interpret
this finding.
In the SHEEP study, IL6R haplotypes carrying the A allele at rs8192284 were associated
with lower serum levels of sIL6R, as compared to the reference haplotype, and explained about
9% of the variance in serum sIL6R levels. The sIL6R is released in the circulation mainly
through the shedding (proteolytic cleavage) of the extracellular domain of the membrane
bound IL6R and via the transcription of an alternative spliced mRNA lacking a sequence of 90
base pairs that encodes the transmembrane domain of the membrane bound receptor. The ge-
netic variant rs8192284A/C introduces an Asp to Ala aminoacid change in the membrane
bound receptor at the soluble receptor shedding site. It has recently been shown that presence
of the CC genotype is associated with an increased shedding of the receptor and an increased
expression and release of the alternatively spliced receptor [24]. The contribution of the sIL6R
derived from the spliced variant to the total circulating sIL6R is relatively low, however, it has
been shown that sIL6R serum levels vary with age and are increased in hepatic disorders and in
acute T-cell leukaemia [25]. The assay used in the present study does not discriminate between
the two circulating forms of sIL6R, therefore, we cannot analyse the selective association of
IL6R haplotypes with each one of the two sIL6R forms. In addition to rs8192284, two SNPs in
almost complete LD with two of the SNPs analysed here (rs8192282 in haplotype block 2 and
rs12083537 in haplotype block1) have been shown to have a small effect on circulating levels of
sIL6R [24]. In our analysis all haplotypes carrying the A allele at rs8192284 in haplotype block
2 contribute equally to reduce receptor serum levels, thus suggesting that rs8192284 and
rs8192282 influence serum sIL6R levels independently from each other. Haplotypes in block 1
were not associated with serum sIL6R levels in SHEEP. A recent report indicates that allele A
at rs12083537 was associated with a slight increase in serum sIL6R levels and an increased risk
of asthma in two large cohorts [26]. These findings indicate that IL6R haplotypes may contrib-
ute to define genetic risk profiles for inflammatory diseases.
We tested the association of IL6R haplotypes with inflammatory biomarkers in the control
group of the SHEEP study and used the same strategy in the two replication cohorts, to avoid
the confounding effect of the case status.
Our current data indicate that IL6R haplotypes are not significantly associated with risk of
CHD in three large European studies. Haplotypes in block 2 contain two SNPs (r2 = 0.46) for-
merly associated with the risk of CHD. SNP rs4553185T/C (in position 2) in full LD with
rs4845625C/T, was associated with a 4% increase in the CHD risk in the CARDIoGRAM-C4D
Consortium [1] and SNP rs8192284A/C (in position 3) with a 5% decrease in the risk of CHD
[2–4]. The apparent controversy between the single SNP and the haplotype analysis may have
several explanations. The biological value of haplotypes differs from that of single SNPs
[27,28]. Haplotypes mirror the changes that sequential nucleotide variants impose on the ami-
noacid sequence and are able to catch subtle changes in the protein function, probably mediat-
ed by alteration in secondary or tertiary protein structure, and the effect of a single variant is
analyzed in the context of the haplotypic background, regardless of its causality [7,9]. IL6R ge-
netic variants have a rather small effect on the MI/CHD risk and populations of larger size may
be needed to detect the effect of haplotypes where the effect of alleles with an opposite effect on
the CHD risk may average when analyzing the haplotype as a unique allele. At the same time,
since shedding of the sIL6R from the membrane bound IL6R receptor is increased in the pres-
ence of the rs8192284C allelic variant while it is reduced in the presence of other mutations
surrounding the cleavage site [29], we cannot exclude that possibility non-genetic mechanisms
related to the sIL6R stability in the circulation are involved in the regulation of biological pro-
cesses with a central role in atherogenesis. (Fig. 2).
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Of note, a relevant clinical implication of this property of haplotypes is the possibility to bet-
ter identify responders to specific treatments, as shown for example for the beta 2 receptor hap-
lotypes that modify bronchodilator response to beta agonist in asthmatics [27], and to generate
individually tailored cardiovascular risk profiles [13].
Several limitations of our study need to be acknowledged. The SNP choice in the present
study was based upon tag SNPs in IL6R according to the HapMap data release 24 and integrat-
ed with SNPs included in the Illumina 200K CardioMetabochip and therefore does not include
SNPs recently added to the Hap Map database. Demonstration of association of IL6R haplo-
types with serum levels of IL6, IL8, sIL6R and TNF-α is limited to the SHEEP study. All the
three study populations have been recruited in Europe, and therefore our results cannot be ex-
tended to other ethnicities since the pairwise LD values and therefore the haplotype structure
differs amongst populations.
In conclusion, our data provide strong evidence that IL6R haplotypes selectively regulate
circulating levels of inflammatory biomarkers that constitute relevant indicators of cardiovas-
cular risk but have a modest non significant effect on the risk of CHD. They also support the
notion that haplotype analysis may identify genetic profiles differentially associated with serum
levels of biomarkers and with the risk of complex diseases [30] as well as the responsiveness to
pharmacological treatments.
Fig 2. IL6R haplotypes selectively regulate inflammatory biomarkers. In particular, changes in CRP and fibrinogen are mirrored by inverse
changes in sIL6R serum levels.Mutations around the shedding site may affect the shedding/alternative splicing and therefore the relative amount of sIL6R
in the circulation. The sIL6R, once released participates in the IL6 transignalling in cells not expressing IL6R (i.e. endothelial and smooth muscle cells) and
the complex IL6/sIL6R is buffered in the circulation by its natural antagonist, sgp130. It is possible that the final effect of IL6R haplotypes on the CHD risk
depends on the average effect of the association of different SNPs with the CHD risk present in the same haplotype and/or it may reflect changes in the
secondary and tertiary structure of the IL6R and sIL6R that may affect the IL6/sIL6R interaction with its downstreammediators.
doi:10.1371/journal.pone.0119980.g002
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